The French Competition Authority fines a pharmaceutical company for disparaging competing generics (Sanofi-Aventis)

The French Competition Authority has handed down a fine of EUR 40 million to the Sanofi-Aventis Laboratory for implementing a practice of driving out competition by disparaging generic versions of its flagship product Plavix® to healthcare professionals in order to favor sales of the original product and Sanofi-Aventis’ own generic version, Clopidrogel Winthrop®. A complaint and a request for interim measures was filed against Sanofi-Aventis’ communication strategy by Téva Santé, French subsidiary of the world’s number 1 generic medicine producer. The

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Vogel & Vogel (Paris)

Citation

Joseph Vogel, The French Competition Authority fines a pharmaceutical company for disparaging competing generics (Sanofi-Aventis), 14 mai 2013, e-Competitions May 2013, Art. N° 52523

Visites 457

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues